Integrating Immunotherapy and Nanotechnology in Advanced Drug Delivery Systems for Precision Cancer Therapy
DOI:
https://doi.org/10.61427/jcpr.v4.i1.2024.119Keywords:
Immunotherapy, Nanotechnology, Precision Cancer TherapyAbstract
This review article investigates recent advancements in drug delivery systems, with a specific emphasis on integrating nanotechnology and immunotherapy for precision cancer therapy. This review explores the design, development, and optimization of novel drug delivery platforms aimed at improving drug efficacy, minimizing side effects and enhancing patient outcomes. The synergistic interplay between nanocarriers and immunotherapeutic agents shows significant potential in addressing current challenges in cancer treatment, such as drug resistance and off-target effects. This article reviews recent preclinical and clinical studies, highlighting the transformative potential of these innovative approaches to reshape cancer therapeutics and facilitate the advent of personalized medicine in oncology. The research findings contribute to the ongoing initiatives aimed at refining the effectiveness and safety of pharmaceutical interventions, bringing us one step closer to more efficient and targeted cancer treatments.
Downloads
References
Friess H et al. LHRH receptors in the human pancreas. Basis for anti-hormonal treatment in ductal carcinoma of the pancreas. Int. J. Pancreatol., 1991;(10) : 151-9.
Abdillahi HS et al. South African plants and male reproductive healthcare: conception and contraception. J. Ethnopharmacol, 2012; 143: 475-80.
Marwa Hamdi et al. Design of blue crab chitosan responsive nanoparticles as controlled-release nanocarrier: Physicochemical features, thermal stability and in vitro pH-dependent delivery properties. International Journal of Biological Macromolecules, 2020; 145: 1140-54.
Mengdi Song et al. A nano-targeted co-delivery system based on gene regulation and molecular blocking strategy for synergistic enhancement of platinum chemotherapy sensitivity in ovarian cancer. International Journal of Pharmaceutics, 2023; 640:123022.
Hawkey NM, Sartor AO, Morris MJ, Armstrong AJ. Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches. Clin Adv Hematol Oncol. 2022 Apr;20(4):227-38.
Erika AK, Fletcher et al. Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism of action of immune-therapeutics. International Immuno-pharmacology, 2018; 54: 1-11.
Sedigheh Jalali et al. Examining the impact of immunosuppressive drugs on antibody-dependent cellular cytotoxicity of human peripheral blood natural killer cells and gamma delta (??) T cells. Transplant Immunology, 2024; 82: 101962.
Katarzyna Ratajczak et al. Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening. Biosensors and Bioelectronics, 2023; 240: 115644.
Michael Babich et al. A distinct pan-adenocarcinoma diagnostic and immunotherapeutic tumor specific antigen. Heliyon, 2022; 8(3): e08988.
Haoyu Chen et al. Triple-Hop nano-bomb combining CDT, PDT and immunetherapy for NIR-triggered cancer therapy. Chemical Engineering Journal, 2024;481:148268.
Mehdi Chaib et al. Sipe PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8+ T cells in breast cancer. Cancer Letters, April 2022; 531: 98-108.
Md Kamrul Hasan et al. Development and Testing of a Glycoengineered Anti-ROR1 Antibody with Enhanced Capacity for Directing Antibody-Dependent Cellular Cytotoxicity (ADCC) of Chronic Lymphocytic Leukemia Cells. Blood, 2023;142, (1): 26836.
Chu AK et al. The Supportive Care Needs of Advanced Lung Cancer Patients Receiving Immuno- and Targeted Therapy at Different Stages of the Disease Trajectory. Journal of Thoracic Oncology, 2023; 18(11): S742.
Nayak RK, Gerber D, Zhang C, Cohen JB. SOHO State of the Art Updates and Next Questions Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors. Clin Lymphoma Myeloma Leuk. 2023 Dec; 23(12):861-5.
Mohammad Saleh Sadeghi et al. Graphene oxide nanoarchitectures in cancer therapy: Drug and gene delivery, phototherapy, immunotherapy, and vaccine development. Environmental Research,2023; 237(2): 117027.
Michelle Harriz Braga et al. Risk factors for cancer in patients with primary biliary cholangitis and autoimmune hepatitis and primary biliary cholangitis overlap syndrome. Annals of Hepatology, 2023; 28(4): 101105.
Devesh U Kapoor et al. Garg Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer. Results in Chemistry, 2023; 6:101167.
Lima EABF, Wyde RAF, Sorace AG, Yankeelov TE. Optimizing combination therapy in a murine model of HER2+ breast cancer. Comput Methods Appl Mech Eng. 2022 Dec 1; 402:115484.
Auletta JJ, Sandmaier BM, Jensen E, Majhail NS, Knutson J, Nemecek E, Ajayi-Hackworth F, Davies SM; ACCESS Workshop Team. The ASTCT-NMDP ACCESS Initiative: A Collaboration to Address and Sustain Equal Outcomes for All across the Hematopoietic Cell Transplantation and Cellular Therapy Ecosystem. Transplant Cell Ther. 2022 Dec; 28(12):802-9.
Piranfar A, Soltani M, Kashkooli FM, Uribe CF, Rahmim A. Spatiotemporal modeling of radiopharmaceutical transport in solid tumors: Application to 177Lu-PSMA therapy of prostate cancer. Comput Methods Programs Biomed. 2024; 245: 108004.
Akshansh Sharma et al. Recent advancements in photodynamic therapy and cancer biosensor using natural products. Talanta Open, 2023; 8:100261.
Wenpan Li et al. Nanotechnology-enabled immunogenic cell death for improved cancer immunotherapy. International Journal of Pharmaceutics, 2023; 634: 122655.
Zhangyi Luo et al. Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy. Cancer Letters, 2023; 575: 216396.
Xiaogang Qu et al. Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy. Bioactive Materials, 2023; 24:136-52.
Bo Chen et al. Nano-co-delivery of an NIR photothermal agent and an acid-responsive TLR7 agonist prodrug to enhance cancer photothermal immunotherapy and the abscopal effect. Biomaterials, 2024; 305: 122434.
Junnan Li et al. Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment. Drug Resistance Updates, 2023; 66:100904.
Kefeng Liu et al. A novel multifunctional vaccine platform with dendritic cell-targeting and pH-responsive for cancer immunotherapy: Antigen-directed biomimetic fabrication of a cabbage-like mannatide-zinc-antigen hybrid microparticles. Chemical Engineering, 2021; 426: 130867.
Virender Kumar et al. Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles. Cancer Letters, 2023; 579: 216462.
Lu Shi et al. Cell membrane-camouflaged liposomes and neopeptide-loaded liposomes with TLR agonist R848 provides a prime and boost strategy for efficient personalized cancer vaccine therapy Nanomedicine: Nanotechnology, Biology and Medicine. 2023; 48: 102648.
Preeti Sakore et al. The theranostic potential of green nanotechnology-enabled gold nanoparticles in cancer: A paradigm shift on diagnosis and treatment approaches. Results in Chemistry, 2024; 7: 101264.
Weiguo Chen et al. Hypoxia-responsive immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy for potentiating cancer immunotherapy. Chemical Engineering Journal, 2023; 451: 2138781.
Fanqi Liu et al. A versatile nano-transformer for efficient localization-specific imaging and synergistic therapy of bladder cancer. Nano Today, 2024; 54: 102116.
Bartkowski M, Bincoletto V, Salaroglio IC, Ceccone G, Arenal R, Nervo S, Rolando B, Riganti C, Arpicco S, Giordani S. Enhancing pancreatic ductal adenocarcinoma (PDAC) therapy with targeted carbon nano-onion (CNO)-mediated delivery of gemcitabine (GEM)-derived prodrugs. J Colloid Interface Sci. 2024; 659: 339-54.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- V. Jyothi Krishna, Ch. Kesari, Impact of Gene Therapy and Genetic Mutations in Rare Diseases , Journal of Clinical and Pharmaceutical Research: JCPR Volume:4/Issue:1 (2024)
.